CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel) ...Middle East

SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the completion of enrollment in the pivotal Phase II...

Hence then, the article about carsgen announces enrollment completion in china gc gej pivotal phase ii clinical trial of the first in class claudin18 2 car t satri cel was published today ( Monday 19/08/2024 - 03:53 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel) )

Also on site :

• Child Psychologists Are Begging Parents and Grandparents To Stop Asking Kids This Question (and What To Ask Instead)
• Ousted L3Harris CEO Chris Kubasik forfeits $45 million—but he’ll still walk away with $80 million in stock and options
• ‘Dancing with the Stars: The Next Pro’: Witney Carson Arrives to Judge a Brutal Coaching Challenge — See Who Went Home